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Abstract
The mood stabilizing agents lithium chloride (LiCl) and sodium valproate (VPA) have recently
gained interest as potential neuroprotective therapeutics. However, exploitation of these
therapeutic applications is hindered by both a lack of molecular understanding of the mode of
action, and a number of sub-optimal properties, including a relatively small therapeutic window
and variable patient response. Human neuroblastoma cells (SH-SY5Y) were exposed to 1 mM
lithium chloride or 1 mM sodium valproate for 6 h or 72 h, and transcriptomes measured by
Affymetrix U133A/B microarray. Statistically significant gene expression changes were identified
using SAM software, with selected changes confirmed at transcript (TaqMan) and protein
(Western blotting) levels. Finally, anti-apoptotic action was measured by an in vitro fluorescent
assay. Exposure of SH-SY5Y cells to therapeutically relevant concentrations of either lithium
chloride or sodium valproate elicited 936 statistically significant changes in gene expression.
Amongst these changes we observed a large (maximal 31.3-fold) increase in the expression of the
homeodomain protein Six1, and have characterized the time- and dose- dependent up-regulation
of this gene in response to both drugs. In addition, we demonstrate that, like LiCl or VPA
treatment, Six1 over-expression protects SH-SY5Y cells from staurosporine-induced apoptosis via
the blockade of caspsase-3 activation, whereas removal of Six1 protein via siRNA antagonises the
ability of LiCl and VPA to protect SH-SY5Y cells from STS-induced apoptosis. These results
provide a novel mechanistic rationale underlying the neuroprotective mechanism of LiCl and
VPA, suggesting exciting possibilities for the development of novel therapeutic agents against
neurodegenerative diseases such as  Alzheimer’s or Parkinsonism.
Keywords: Bipolar Disorder; Neuroprotection; Lithium chloride; Sodium valproate; Microarray;
Apoptosis
Introduction
Lithium chloride (LiCl) and the anticonvulsant valproate (VPA) are frontline treatments for
the manic phase of bipolar disorder (BD), acting as mood stabilizers (McElroy et al., 1992). The
quoted prevalence for BD is approximately one percent of the population (Spearing, 2001),
although several factors probably result in under- or misdiagnosis. First, there are many BD
phenotypes, complicating diagnosis (Thomas, 2004; MacQueen et al., 2005). Second, from these
multiple phenotypes several variants exist in which one or other phase is extremely mild. Third,
the combination of the previous two factors result in frequent incorrect diagnosis of BD as
unipolar disorder (Dunner, 1992; Spearing, 2001) meaning that the actual prevalence may be
considerably higher. In addition to this  established therapeutic area, increasing support is being
given towards the use of LiCl and VPA as general neuroprotective agents, with potential
treatments including disorders such as Alzheimer’s or Parkinsonism (Brunello, 2004; Aghdam
and Barger, 2007), although the molecular rationale behind this has yet to be elucidated (Di
Daniel et al., 2005). This combined therapeutic arena, encompassing both mood stabilization and
neuroprotection means that the potential patient population who may be subject to chronic
treatment with these therapeutic agents is very large. Unfortunately, in addition to possessing
unknown molecular mode of action(s), both LiCl and VPA have several other sub-optimal
parameters. First, for  treatment of bipolar disorder only around 50 % of patients respond to LiCl
therapy and a similar number (54 %) to VPA treatment (Mendlewicz et al., 1999). Second, both
LiCl and sodium valproate have relatively small therapeutic indices (Strakowski et al., 2001).
Third, both LiCl and VPA require high dosing levels (millimolar circulating concentrations) to
achieve efficacy (Jann et al., 1982; Balfour and Bryson, 1994). It is thus clear that in order to
optimize the use of these agents and/or develop novel therapeutics it is necessary to fully
understand their molecular actions.
Both LiCl and VPA, along with other mood stabilizing agents, elicit wide-ranging effects on
neural cells, including a shared ability to protect against apoptotic insults (Chuang, 2004). Several
investigations have suggested that inhibition of glycogen synthase kinase 3 beta (GSK3?) is a
central component to both their mood stabilization and neuroprotective abilities (Bijur and Jope,
2000; Li et al., 2002b). However, other studies have proposed mechanisms centred around p53
modulation (Lu et al., 1999), phosphatidyloinositol signalling (Ding and Greenberg, 2003),
histone deacetylase inhibition (Phiel et al., 2001) or endoplasmic reticulum dysfunction (Kim et
al., 2005). There is thus a need for further studies to understand how these individual effects
combine to produce the known phenotypic effects of these agents.
To begin to understand the molecular mode of action of both LiCl and VPA in neural cells we
have used DNA microarray analysis to examine changes in the transcriptome of human SH-SY5Y
neuroblastoma cells in response LiCl and VPA. Concentrations used were within the therapeutic
range, with patient serum levels range from 0.8-2 mmol/L for LiCl (Sproule, 2002) and 0.3-0.8
mmol/L for VPA (Allen et al., 2006), with brain concentrations expected to be similar due to the
good ability of both compounds to cross the blood-brain barrier. Both agents elicit a marked rise
in the expression of the cell differentiation factor Six1, and we demonstrate that this increase is
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central to the ability of both LiCl and VPA to exert their neuroprotective effect.
Methods and Materials
Cell Culture
SH-SY5Y cells (ECACC 94030304), a human neuroblastoma cell line, were obtained from
ECACC (Porton Down, Wilts, UK) and Bristol University.  Cells were routinely cultured in
DMEM:F12 supplemented with 10% foetal calf serum, 50 U/ml penicillin and 50 ?g/ml
streptomycin. All cell culture consumables were purchased from Invitrogen (Paisley,UK).
As indicated, a Six1 expression plasmid, or control plasmid, was transfected into SH-SY5Y
cells using FuGENE 6 (Roche Diagnostics, Lewes, UK), along with a GFP expression plasmid
(BD Biosciences) to act as an internal control. Cells were then incubated for 48 hours before the
addition of 1 ?M STS (STS) for 16 hours
For siRNA experiments pre-designed Six1 silencer siRNA (Ambion, Warrington, UK) was
transfected into cells using the Silencer siRNA transfection system (Ambion) as per
manufacturer’s recommendations, with two separate siRNAs against Six1 used to ensure
specificity of response. In addition, a pre-designed silence siRNA against HCaRG was used to
control for off-target effects.
DNA Microarray and Analysis
SH-SY5Y cells were seeded at 2.4 x 105 cells/cm2 in 25 cm2 flasks and allowed to attach
overnight. Cells were dosed daily with 1 mM lithium chloride (Sigma Aldrich, Poole, UK), 1 mM
sodium valproate (Sigma Aldrich) or medium control. Following 6 or 72 hours of exposure, total
RNA was isolated from quadruplicate samples using the RNeasy Mini kit (Qiagen, Crawley, UK)
and was quantified using a Nanodrop Agilent 2100 Bioanalyser. Medium was changed 6 hours
prior to the 72 hour time point to control for gene expression elicited by medium shock. In
addition, the quadruplicate biological samples were composed of two samples each from the
ECACC and Bristol-sourced SH-SY5Y cells; sourcing cells from two different sites controls for
site-specific phenotypic changes in cell lines that can potentially obscure the biologically relevant
changes.
Samples were used to interrogate the Affymetrix U133A/B GeneChip set, representing over
47,000 transcripts including approximately 38,500 fully annotated probe sets.
The data generated from the microarray analysis was first normalised using the Affymetrix
algorithm that allows reliable comparison of multiple arrays, minimising differences of non-
biological origin. Next the SAM (Significance Analysis of Microarrays) package (http://www-
stat.stanford.edu/~tibs/SAM/) was used to identify significantly altered gene expressions, and
generate false discovery rate (FDR) values for the analysis. The SAM package offers the
advantage over other microarray analysis tools in that it does not presume equal variance or
independence of genes (or both), scenarios that are often violated in biological systems (Tusher et
al., 2001). SAM settings were for a two class unpaired analysis between, using one hundred
permutations to calculate the differentially expressed gene list. No fold-change threshold was set,
with instead the delta function manually altered to provide a false discovery rate of approximately
1 %. The exception to this is for 72 hours exposure to LiCl, where a false discovery rate of 20 %
was used due to the very low number of differentially expressed transcripts identified when lower
FDRs were used. To examine the potential impact on biological pathways of the identified gene
expression changes the DAVID software suite (http://david.abcc.ncifcrf.gov/home.jsp) was used
to undertake functional annotation clustering, whereby GO identifiers that are statistically over-
represented are clustered according to their biological functions (Dennis Jr et al., 2003).
Transcript level measurement
Primers and TAMRA/FAM dual labelled probe specific for Six1, Bcl2, Bcl2L1 and 18S were
designed using the Primer Express software (Applied Biosystems, Warrington, UK) and were
purchased from MWG (Milton Keynes, UK).
SH-SY5Y cells were seeded at 2.4 x 105 cells/cm2 in 25 cm2 flasks and allowed to attach
overnight. Cells were dosed daily with either varying concentrations of lithium chloride, sodium
valproate or medium control. At specified time points, total RNA was isolated from quadruplicate
samples using the RNeasy Mini kit (Qiagen) and was quantified using a Nanodrop Agilent 2100
Bioanalyser.
Total RNA was treated with RNase-free DNase (Promega, Southampton, UK) to remove
genomic contamination. Reverse transcription was primed with random hexamers and carried out
by Superscript II (Invitrogen) as per the manufacturer’s instructions. To ensure that DNase treated
samples were free from genomic contamination an RT- control (lacking enzyme) was carried out
for every RNA sample. cDNA generated from 50 ng (Six 1) or 50 pg (18S rRNA) of total RNA
was amplified using TaqMan Universal PCR Master Mix with 400 nM primers and 200 nM
fluorogenic probe in a total reaction volume of 25 µl. Quantitative polymerase chain reaction (Q-
PCR) reactions were run on the ABI7000 SDS instrument and quantitation was carried out using
the ABI proprietary software against a standard curve generated from human genomic DNA
(Promega).
Protein level measurement
SH-SY5Y cells were seeded at 2.4 x 105 cells/cm2 in 25 cm2 flasks and allowed to attach
overnight. Cells were dosed daily with either varying concentrations of lithium chloride, sodium
valproate or medium control. Following 72 hours of exposure total protein was extracted in RIPA
buffer (1xPBS pH 7.3, 1% Nonidet P40, 0.5 % sodium deoxycholate, 0.1 % SDS), with 1x
protease inhibitor cocktail solution (Roche, Lewes, Sussex, UK) added just prior to use.
Total SH-SY5Y protein extracts (5 (g per lane) were resolved on 12 % SDS-polyacrylamide
gels and then transferred electrophoretically to Hybond ECL nitrocellulose membranes
(Amersham Biosciences, Little Chalfont, Bucks, UK).  Membranes were blocked (1 hour) in 5 %
fat free dried milk and then probed with primary antibodies against Six1 (sc-9127; 1:400),
cylcinA1 (sc-15383; 1:300) or pax3/7 (sc-7748; 1:300) for one hour (Autogen Bioclear, Calne,
Wilts, UK), followed by anti-rabbit (Six1/CyclinA1; sc-2007; 1:5000) or anti-goat (Pax3/7; sc-
2022; 1:5000) IgG  for one hour (Autogen Bioclear).  Bound antibodies were visualised using
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enhanced chemiluminescence reagents according to the manufactures instructions (Amersham
Biosciences), and opposed to Fuji Super RX film (Fisher Scientific). Computer based
densitometry of gels was undertaken using a GeneGenius Bioimaging System (Syngene,
Frederick, MD).  Immunoblots were also probed with an antibody against ?-actin (ab-8226;
1:1000) for one hour (AbCam, Cambridge, UK), followed by anti-mouse IgG (ab-6728; 1:2000)
for one hour (AbCam)  to ensure even loading per lane.
The phosphorylation status of GSK3? within cells was determined using the  phosphoELISA
assay (Invitrogen) according to the manufacturer’s instructions. Briefly, cells were grown as
described above and extracted into RIPA buffer. pTyr216GSK3? was measured as a marker of the
active enzyme, while pSer9GSK? was measured as a marker of inactive protein.
Cell Death Measurement
SH-SY5Y cells were seeded at 2.4 x 105 cells/cm2 in 25 cm2 flasks and allowed to attach
overnight. For the last 16 hours of cell treatment, cells were exposed to 1 µM staurosporine (STS),
as indicated, to induce apoptosis. Cell Death was measured by LDH-leakage using the
cytotoxicity detection kit (Roche), as per the manufacturer’s instructions. LDH measurements
were normalised to medium-only (0 % cell death) and 0.1 % (v/v) Triton X100-lysed cells (100 %
cell death). Caspase-1 and Caspase-3 activity was measured using the CaspACE assay system
(Promega), according to the manufacturer’s instructions. Briefly, following exposure to STS, cells
were washed in PBS, resuspended in hypotonic lysis buffer (25 mM HEPES, pH 7.5, 5 mM
MgCl2, 5 mM EDTA, 5 mM DTT, 1x protease inhibitor cocktail (Roche)) and lysed by four
cycles of freeze-thaw, followed by centrifugation at 16,000 g for 20 minutes at 4 (C. Supernatants
were mixed with specific fluorogenic substrates (Ac-DEVD-AMC or Ac-YVAD-AMD for
caspase-3 and -1 respectively), incubated for 1 hour at 30 (C, and then substrate turnover
measured using a Molecular Dynamics  SpectraMax Gemini XS with excitation and emission
wavelengths of 360 nm and 460 nm respectively.
Results
Microarray analysis of SH-SY5Y transcriptome following exposure to LiCl or VPA
Exposure of SH-SY5Y cells to mood stabilizing agents for 6 hours provides information on genes
whose expression are likely to be affected directly by the action of LiCl and VPA (i.e. primary
targets). In comparison, exposure to LiCl and VPA for 72 hours provides a measure of
transcriptome changes caused by both direct and indirect effects of these chemicals on the SY-
SY5Y transcriptome. SH-SY5Y cells from two different sources were used in the microarray
experiment to control for potential source-specific phenotypes that could act as confounders to
interpretation of the data. Correlation analysis between the transcriptome of the ECACC- and
Bristol-sourced SH-SY5Y control cultures showed no significant variance at either the 6 or 72
hours time points (Figure 1A). Following exposure of cells to either LiCl or VPA the
transcriptomes were still highly correlated (r2>0.98 in all cases), and hence results from ECACC-
and Bristol-sourced SH-SY5Y cells were pooled for microarray analysis, increasing the power of
the experiment. Figure 1B-E shows the Significance Analysis of Microarrays (SAM) output plot
for each of the test conditions, with the correlation analysis between the two cell sources included
as an inset. Each SAM plot details the number of altered genes identified for the specified False
Discovery Rate (FDR), with more detailed information on the number and direction of these
changes is provided in table 1. It can be seen that at a therapeutically relevant, equimolar,
concentration (1 mM) VPA has a much larger impact on the SH-SY5Y transcriptome compared to
LiCl, with VPA elicited 922 changes compared to only 14 changes elicited by LiCl. The full list
of altered genes is presented as supplementary information. As no significant difference in
transcriptome response was observed between ECACC- and Bristol-sourced cells in response to
either LiCl of VPA exposure the ECACC-sourced cell line was chosen for all subsequent
experiments due to its increased general availability.
A further refinement of transcriptome analysis was undertaken using the DAVID
bioinformatic suite to interrogate Gene Ontology (GO) identifiers of transcripts altered by
chemical treatment. As GO identifiers refer to biological processes rather than individual reactions
any over-representation in a dataset is often indicative of a significant impact on the pathway(s)
associated with the GO identifiers. Table 2 shows the main GO identifiers shown to be over-
represented in the microarray data, with the number of genes associated with each treatment/GO
identifier indicated. SH-SY5Y exposure to VPA elicited the largest number of significantly over-
represented GO identifiers, consistent with the larger number of genes altered by this drug in
comparison to LiCl. In general, GO identifiers over-represented after 6 hours were also seen at 72
hours, but with more altered genes associated with them, a logical consequence of a more
developed biological response to chemical exposure. The exception to this are the GO identifiers
grouped under ‘cell communication’, which generally decline in number between the early and
late time points of the microarray analysis. This is perhaps not unsurprising given that
transmission of cellular signals should logically occur early in a response, with endpoint changes
such as metabolic capacity occurring later, possibly as a result of these signalling pathways.
LiCl and VPA alter Six1 expression in SH-SY5Y cells
Amongst those genes whose expression was altered by VPA exposure, the homeobox gene sine
oculis 1 (Six1) showed one of the largest changes, being up-regulated by 31.3 fold following 72
hours of exposure. Examination of the microarray dataset revealed that LiCl also caused a
statistically significant increase in Six1 gene expression although to a smaller magnitude, being
1.7 fold by 72 hours. Due to this small fold-change, Six1 does not appear in the list of LiCl-
altered genes presented as supplementary material, being one of those within the false negative
group. To correctly identify Six1 as being significantly increased within this group would require
an FDR of 83.5 %, resulting in an unacceptably high number of false positives. Gene expression
of Six1 is not significantly altered by 6 hours treatment with either LiCl or VPA, suggesting that
the affect is due to an indirect action of these agents on Six1 expression
To confirm and further characterize this change, we next examined the time and dose response
of compound-mediated increases in Six1 transcript levels by TaqMan Q-PCR. Both VPA and
LiCl elicited a dose-dependent increase in Six1 transcript level (Figure 2a), and as observed with
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the microarrays, VPA elicited the larger fold-increase in transcript level (6.8 fold) compared to
LiCl (3.7 fold). Figure 2b demonstrates that the observed increase in transcript levels was
mirrored at the protein level, with 48 hours exposure resulting in significant increases in Six1
protein levels. Specific identification of the Six 1 immunoreactive band was confirmed through
comparison to recombinant Six1. The Six1 antibody used, targeted against amino acids 1-444 of
the protein, detects several other immunoreactive bands and it is possible that these correspond to
different phosphorylation states of Six1, or to other members of the Six family. As the
immunoreactive bands are of sizes comparable to other members of the Six family this would
support the latter scenario, and interestingly several of these also alter following compound
treatment. The induction of Six1 transcript levels in SH-SY5Y cells occurs more rapidly
following exposure to VPA, reaching significance within 18 hours, whereas LiCl exposure
required 48 hours exposure to elicit a statistically significant increase (Figure 2c). A larger fold
increase in Six1 expression is observed following 48 hours treatment with 3mM VPA,
approximately 32-fold, compared to that seen in figure 2a, which is approximately 7-fold.
However this difference is due to a difference in the basal expression of Six1, with the induced
level being approximately 2000 transcripts/ng input RNA in both cases. Both agents are seen to
elicit a response only following a sub-acute exposure, in agreement with the microarray  data, and
this is suggestive that the effect of these agents on Six1 gene expression occurs via an indirect
mechanism.
Six1 contributes to the anti-apoptotic effects of LiCl and VPA
The classical apoptosis-inducting chemical STS was capable of causing 92 % cell death in SH-
SY5Y cells (Figure 3a), and this was accompanied by an increase in caspase-3 activity (205 % of
control), but no change in caspase-1 activity (Figure 3b). Pre-exposure of SH-SY5Y cells to the
anti-mania drugs VPA and LiCl for 48 hours provided partial protection against STS (STS)-
mediated cell death,  and reduced the activation of capase-3 to 145 % and 158 % of control levels
respectively (Figure 3a+b).
In order to investigate potential mechanisms by which this effect could be mediated we
undertook pathway analysis using PathwayArchitect, constructing the model presented in figure
3c. In this model, both LiCl and VPA interact with GSK3?, inhibiting its action. One of the many
cellular targets for GSK3? is beta-catenin, and hence inhibition of GSK3? would lead to an
accumulation of beta-catenin, which in turn activates the expression of a number of factors
including the transcription factor Pax3, a factor that has previously been linked to the Six family.
A downstream target for Six1 is cyclinA1, and we hypothesize that increases in Pax3 and
cyclinA1 would result in increased expression of the anti-apoptotic factors Bcl2L1(Bcl-xl) and
Bcl2 respectively, resulting in the observed protection from STS-induced apoptosis.
To test this hypothetical pathway, we next examined the effect of LiCl and VPA exposure of
SH-SY5Y cells on the expression of factors identified within the hypothetical pathway presented
in figure 3c. Exposure of SH-SY5Y cells to either LiCl or VPA resulted in a dose-dependent
inhibition of GSK3? (figure 4a), as measured by decreased pTyr216-GSK3? (active form) and
increased pSer9-GSK3? (inactive form). Protein levels of Pax3 and cyclinA1 were increased by
both LiCl and VPA in a dose-dependent manner (Figure 4b). Up-regulation of Pax3/cyclinA1 is
proposed to result in increased levels of the anti-apoptotic proteins Bcl2 and Bcl2L1, and figure
4c demonstrates the increased transcript levels for these factors in SH-SY5Y cells following
exposure to LiCl or VPA.
Next, the input of Six1 into the observed neuroprotective effect was examined through over-
expression and knock-down experiments. Over-expression of Six1 reduced STS-induced cell
death in SH-SY5Y cells by 43 %, and this reduction was again associated with an 8 % decrease in
the activation of caspase-3 (Figure 5a+b). This protection from STS-induced apoptosis is not
complete however, demonstrating that other mechanisms also contribute to STS-induced
apoptosis, as reviewed by Gurvich and Klein (Gurvich and Klein, 2002).
Finally, SH-SY5Y cells were transiently transfected with siRNA targeted against Six1, and
then exposed to either VPA or LiCl for 48 hours. Under such a treatment regime, increased
expression of Six1 by compounds was reduced to 131 % and 238 % of control for LiCl and VPA
respectively, compared to 290 % and 878 % without Six1 siRNA treatment (Figure 5c). This
repression was confirmed as specific through the use of both a second siRNA targeted against
Six1, which gave a similar level of knock-down (data not shown). Such data demonstrates that
siRNA treatment was capable of reducing Six1 transcript expression in the cells by up to 73 %,
although further work would be required to show that this effect translated to protein levels. As
previously seen, in cells exposed to LiCl or VPA alone, STS exposure results in significantly
decreased cell death compared to STS alone (24 % and 27 % respectively; Figure 5d). Over
expression of Six1 in SH-SY5Y cells results in an approximately 20% antagonism of the ability of
LiCl or VPA to protect cells from STS-induced apoptosis (Figure 5d).  Transfection of SH-SY5Y
cells with a non-Six1 siRNA, active against hypertension related, calcium regulate gene
(HCaRG), demonstrated that the observed effect was specific and as a result of off-target effects
(Figure 5d). Taken together, such data is strongly supportive of Six1 being the central component
in the ability of LiCl and VPA to inhibit STS-induced apoptosis.
Discussion
The Six family of proteins are vertebrate homologues of the Drosophila sine oculis proteins,
which are involved in cell fate differentiation (Kawakami et al., 2000). Sine oculis family
members interact with the eyeless, eyes absent and dachshund proteins and are central to
Drosophila eye development (Serikaku and O’Tousa, 1994), while their mammalian homologues
(Six1-6, Pax, Eya and Dac respectively) have also been shown to play an important role in
organogenesis (Li et al., 2003; Xu et al., 2003; Zheng et al., 2003). Their expression in specific
migrating cell populations appear to be vital, as both Drosophila and mice null for Six1 are non-
viable, with null mice exhibiting large scale abnormalities in the development of skeletal muscle,
as well as several major organs (Serikaku and O’Tousa, 1994; Laclef et al., 2003). Beyond this
initial identification as crucial regulators during development, six family members have recently
come under the spotlight due to their potential role in tumourogenesis, which is perhaps not
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surprising given their established role in cell migration and differentiation. Six1 has been shown
to regulate cellular proliferation at the G2-M checkpoint (Ford et al., 1998; Ford et al., 2000), to
be over-expressed in a number of tumours (Ford et al., 1998; Li et al., 2002a; Reichenberger et
al., 2005), inhibit apoptosis within ovarian tumours (Behbakht et al., 2007), and has been shown
to be involved in metastasis (Yu et al., 2004). A common feature of tumour development is often
the co-ordinate regulation of both cell proliferation and apoptosis, with up-regulation of the
former and inhibition of the latter being central to mutation fixation and tumour growth
(Roberts et al., 1995; Plant et al., 1998; Pliskova et al., 2005). It is thus interesting that GO
analysis clearly shows that genes associated with both apoptotic cell death and cell cycling are
affected by VPA treatment. Genes up-regulated by 72 hours VPA treatment include several genes
implicated in the inhibition of apoptosis, including pim-1 (Moroy et al., 1993), BAG3 (Silva et
al., 2008), inhibin ?a (Denkova et al., 2004), as well as those associated with growth arrest,
including p21 (Wakabayashi et al., 2000)  and GAS2 (Brancolini et al., 1995). Such statistical
analysis of GO identifier over-expression does not identify the extent of impact on a biological
pathway, merely that more genes in that pathway are altered than would be expected by chance.
This is exemplified by the fact although GO identifiers negative regulation of apoptosis/cell
cycling are over-represented in the genes up-regulated following VPA exposure so are genes
associated with positive regulation, including TGF? (Bursch et al., 1993) and FOXO1
(Fukunaga et al., 2005). Such data is consistent with studies showing that VPA can elicit either
pro-apoptotic (Phillips et al., 2003; Chen et al., 2007) or anti-apoptotic (Brunello, 2004)
responses, with cellular fate presumably being determined by the net flow through these two
opposing pathways under any particular cell/species/biological condition. Herein we demonstrate
that exposure of SH-SY5Y cells to VPA has an inhibitory effect on apoptosis, reducing STS-
mediated cell death, suggesting that in this case the net flow is through the anti-apoptotic
pathway. STS-mediated cell death has previously been shown to occur through the activation of
caspase-3 in SH-SY5Y cells (Posmantur et al., 1997), and we demonstrate that both LiCl and
VPA partially protect (40-50 %) cells from STS through the inhibition of caspase-3 activity.
The molecular mechanisms underlying the many effects of LiCl and VPA on neural cells have
not been fully elucidated at present. In the current study VPA elicited many more alterations to the
SHY-SY5Y transcriptome compared to LiCl, and two potential explanations exist for this. First,
daily dosing of chemicals could have resulted in accumulation of  VPA within cells, effectively
increasing the exposure. However, daily dosing was specifically chosen due to the relatively short
half-life of VPA in culture, approximately 4.5 hours, to ensure an even exposure was obtained.
LiCl has a considerably higher half-life in culture (approximately 30 hours), but the evidence
presented herein is not consistent with an over-exposure to this agent. Second, VPA has a
recognised action as a histone deacetlylase (HDAC) inhibitor (De Sarno et al., 2002), which could
potentially result in a more wide-spread transcriptome effect following exposure. Indeed, recent
work has suggested that the HDAC-inhibitory action of VPA is, at least in part, responsible for the
neuroprotective mechanisms of this chemical (Chen et al., 2007; Kim et al., 2007; Leng et al.,
2008).
A common action of both chemicals in neural cells appears to be inhibition of GSK3?,
although this is caused by different mechanism by the two agents. LiCl is a direct inhibitor of
GSK3? through altered phosphorylation, whereas VPA appears to act both directly and indirectly
via its HDAC inhibitory action (Chen et al., 1999a; De Sarno et al., 2002; Al-Assar and Crouch,
2005). Herein we demonstrate that in human SH-SY5Y cells both LiCl and VPA are able to
inhibit GSK3? activity, which is in line with previous work in this cell line (De Sarno et al.,
2002). Both agents produce a dose-dependent decrease in the active pTyr216-GSK3?, while
increasing pSer9-GSK3? by up to 300 %. A multitude of biological roles have been identified for
GSK3? (Jope and Johnson, 2004), and hence it is not a simple process to understand the
consequences of GSK3? inhibition by LiCl and VPA. Increased levels of GSK3? have been
associated with increased apoptosis in SH-SY5Y cells (Bijur and Jope, 2000) and ultimately
neurodegeneration in mice (Lucas et al., 2001), and hence this has led to the suggestion that
GSK3? inhibition may play a role in the known neuroprotective actions of both LiCl and VPA in
humans (Brunello, 2004). Herein we confirm that both LiCl and VPA are able to protect neural
cells from STS-mediated cell death, and show that this is due to decreased activity of caspase-3.
Over-expression of Six1 in SH-SY5Y cells only results in an 8 % decrease in capase-3 activity
following STS exposure, but this is accompanied by a 42 % decrease in cell death. The
explanation for this disparity is not clear, but may be a reflection of the sampling time point (16
hours of STS exposure), at which point many cells will be committed to, or have undergone, cell
death and hence caspace-3 measurements are an underestimate. In addition, we present evidence
to support a novel molecular pathway downstream of GSK3? inhibition that could mediate this
effect. This model has been generated through a text-mining approach, whereby interactions
between proteins, regardless of species or tissue of origin, are organised into a network. Whereas
this has the advantage that it can utilise a large literature base for construction of the pathway, it is
important to note that as species- and/or tissue-specific signalling pathways may exist the
generated pathway must be confirmed experimentally in the tissue of interest. The degradation of
beta-catenin is controlled by GSK3? in a host of cell types, including neurons (Novak and Dedhar,
1999; Kimelman and Xu, 2006), and hence inhibition of GSK3? would lead to an accumulation of
beta-catenin target genes. Amongst these targets is the transcription factor Pax3, which has
previously been shown to regulate transcription of Six1 in murine embryonic cardiomyocytes
(Petropoulos and Skerjanc, 2002), with both  Pax and Six family members being central to murine
neural development (Wlodarczyk et al., 1996). Herein we demonstrate that LiCl and VPA
treatment results in increased protein levels of Pax3, Six1 and cyclinA1 in human neuroblastoma
cells. Whereas we do not demonstrate a causal relationship between the increase in these protein
levels in the current work,  the previously demonstrated inter-relationships of Pax3 and Six1
(Petropoulos and Skerjanc, 2002) and the interaction of Six1 and CyclinA1 in murine embryonic
fibroblasts  (Coletta et al., 2004) suggest that one may exist, allowing us to present the
hypothetical pathway shown in figure 3. Pax3 and cyclinA1 have been previously linked to the
expression of the anti-apoptotic factors Bcl2L1(Bcl-xl) and Bcl2 respectively in murine liver
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(DelaCoste et al., 1999; Wakabayashi et al., 2000), and we demonstrate herein that the increased
levels of Pax3 and CyclinA1 correlate with increased transcript levels for both Bcl2 and Bcl2L1 in
human SH-SY5Y cells. The observed increases in Bcl2 family members is in agreement with
previous work that chronic LiCl and VPA treatment increased Bcl2 expression levels in rat brain
(Manji et al., 2001) and Bcl2 activity, both in SH-SY5Y cells in vitro (Yuan et al., 2001) and rat
frontal cortex in vivo  (Chen et al., 1999b). The increased activity of these two anti-apoptotic
factors would explain the observed decrease in caspase-3 activity in response to STS, and as
inhibition of caspase activity has previously been linked to neuroprotection (Ray, 2006) we
propose that this pathway is contributing to the ability of LiCl and VPA to act as neuroprotective
agents. The protective ability of both LiCl and VPA against a number of other pro-apoptotic
stimuli has been previously described, including ischemic stroke (Kim et al., 2007) and glutamate
(Leng et al., 2008), with GSK3? inhibition appearing to play a central role in both processes. The
current work demonstrates that both LiCl and VPA have the ability to protect neural cells from
STS-induced apoptosis and that this is also associated, at least in part, with inhibition of GSK3?.
In summary, we have identified Six1 as a signalling molecule through which LiCl and VPA
protect neuroblastoma cells against STS-induced apoptosis, lending weight to the potential role of
these therapeutics for neuroprotection. Moreover, we propose a hypothetical model, based upon
existing literature, for their neuroprotective action, centred on the increased expression of the
homoedomain protein Six1 by both drugs, and provide supporting evidence for it. More studies
are needed to elucidate other pathways that also contribute to caspase-3 activation in these cells,
and this may help in the development of new exciting strategies for neuroprotection.
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Figure Legends
Figure 1: Gene expression profile in SH-SY5Y cells exposed to anti-mania agents.
Quadruplicate cultures of SH-SY5Y cells (two cultures each from ECACC- and Bristol-sourced
cells) were exposed to 1mM LiCl, 1mM VPA or medium for 6 or 72 hours. RNA was extracted
and transcript levels monitored using Affymetrix human U133A/B microarrays. (A) Control
cultures from both sources had highly correlated transcriptomes after 6 hours and 72 hours of
culture. Statistical Analysis of Microarray (SAM) outputs are presented (Dose vs medium)
following 6 hours of LiCl (B) or VPA (C) exposure, and 72 hours of LiCl (D) or VPA (E)
treatment, showing observed versus expected scores and the lines of equivalence and significance.
The number of regulated genes, plus the expected false positives for the indicated false discovery
rate (FDR) are also indicated. Correlation analysis of the SH-SY5Y transcriptome from the two
cell sources under each experimental condition is included as an inset figure.
Figure 2: Time and dose dependent increased Six1 expression elicited by LiCl and VPA
exposure. SH-SY5Y neuroblastoma cells were exposed to VPA or LiCl at the indicated
concentrations for 48 hours and then Six1 expression measured at the transcript level using
TaqMan Q-PCR (A) and the protein level by Western blotting with TNT-expressed Six1 used as a
positive control.  Protein expression was determined by densitometry (n=3), normalised to actin
levels, and displayed as fold increase over vehicle control ±SEM (B). For time course experiments
cells were exposed to 3mM of compound (closed bars) or medium (open bars) for the indicated
times and then Six1 transcript level measured via quantitative PCR for n=4±SEM (C). Statistical
analysis was via one-way ANOVA; *=p<0.01, **=p<0.05 and ***=p<0.01.
Figure 3: Putative molecular mechanism for LiCl and VPA-induced neuroprotection.
SH-SY5Y neuroblastoma cells were exposed to 3mM LiCl or 3mM VPA for 48 hours, with 1?M
STS added for the final 16 hours as indicated. Cell death was then measured by LDH assay (A)
and caspase-1/caspase-3 activity fluorimetric assay (B). For all experiments, data represents
n=4±SEM, with statistical analysis via one- or two way ANOVA as applicable; *=p<0.01,
**=p<0.05 and ***=p<0.01 and figure is representative of duplicate repeat experiments. (C)
Pathway Architect software was used to develop a putative molecular mechanism by which LiCl
and VPA could act inhibit apoptosis: LiCl and VPA inhibit, either directly or indirectly, GSK3?,
which results in the observed increases in Pax3, Six1 and CyclinA1. Known target genes for Pax 3
and CyclinA1 are the anti-apoptotic proteins Bcl2L1 and Bcl2 respectively. Increased levels of
these proteins result in blockade of caspase-3-mediated apoptosis and, ultimately, neuroprotection.
Figure 4: LiCl and VPA increase the expression of Pax3, cyclinA1 and anti-apoptotic
members of the Bcl2 family.
SH-SY5Y neuroblastoma cells were exposed to VPA or LiCl at the indicated concentrations for
48 hours and then GSK3? phosphorylation status measured by ELISA (A). Pax3, CyclinA1 and
Actin protein levels were measured by Western blotting, with TNT-expressed Pax3 and CyclinA1
used as a positive control.  Protein expression was determined by densitometry (n=3), normalised
to actin levels, and displayed as fold increase over vehicle control ±SEM (B). Bcl2 and Bcl2L1
transcript levels were measured by TaqMan Q-PCR (n=4 ±SEM) (C). Statistical analysis was via
one-way ANOVA; *=p<0.01, **=p<0.05 and ***=p<0.01. 
Figure 5: Six 1 is central to the LiCl and VPA-mediated neuroprotection against STS
induced apoptosis in SH-SY5Y cells
Six1 was over-expressed in SH-SY5Y cells, which were then exposed to 1?M STS or medium for
16 hours and then cell death measured using LDH assay (A) and caspase-1/caspase-3 activity
measured using a fluorimetric assay (B). In addition, SH-SY5Y neuroblastoma cells were exposed
to 3mM LiCl or 3mM VPA for 48 hours, with 1?M STS added for the final 16 hours as indicated;
wells were also transfected with siRNA targeted against Six1. Successful knockdown of Six1 was
determined  by quantitative PCR and Western blotting. An off-target siRNA (HCaRG) was
included as a negative control (C). Cell death was measured using LDH assay, including siRNAs
against both Six1 and HCaRG (D). Each data point represents n=4 ±SEM. Statistical analysis was
via one- or two way ANOVA as applicable; *=p<0.01, **=p<0.05 and ***=p<0.01 and is
representative of at least duplicate repeat experiments.
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|Treatment |Time  |FDR  |Genes   |Gene      |Gene      |Predicted|
|          |      |     |changed |Expression|Expression|False    |
|          |      |     |        |Increased |Decreased |Positives|
|1mM LiCl  |6h    |1%   |0       |0         |0         |0        |
|1mM VPA   |6h    |1%   |155     |121       |34        |1.49     |
|1mM LiCl  |72h   |20%  |14      |14        |0         |2.85     |
|1mM VPA   |72h   |1%   |767     |637       |130       |8.3      |
Table 1: Gene expression changes elicited by LiCl and VPA in SH-SY5Y cells. Quadruplicate
cultures of SH-SY5Y cells were exposed to 1mM LiCl, 1mM VPA or medium for 6 or 72 hours
as indicated. RNA was extracted and gene expression monitored using Affymetrix human
U133A/B microarrays. Statistical Analysis of Microarrays (SAM) analysis was undertaken to
identify statistically significant gene expression changes (Dose vs medium). False Discovery Rate
(FDR) was manually set to provide sufficient gene changes, while limiting the number of
predicted false positives. Numbers of genes altered under each condition are presented for the
stated FDR, along with the predicted number of false positives within each group.
|Biological Process                   |VPA 6h  |VPA 6h  |LiCl 72h  |VPA 72h   |VPA 72h  |
|                                     |Up      |Down    |Up        |Up        |Down     |
|Antigen presentation                 |        |        |          |8         |         |
|Biosythesis                          |8       |        |          |36        |20       |
|        Protein biosynthesis         |3       |        |          |13        |12       |
|        Lipid biosynthesis           |        |        |          |10        |3        |
|        Steroid biosynthesis         |        |        |          |4         |         |
|Cation transport                     |4       |        |          |19        |         |
|        Cation homeostasis           |        |        |          |8         |         |
|Cell Activation                      |        |        |          |6         |         |
|Cell communication                   |18      |        |4         |          |12       |
|        Signal transduction          |16      |        |4         |          |12       |
|        Intracellular siganlling     |12      |        |          |          |6        |
|cascade                              |        |        |          |          |         |
|        small GTPase mediated signal |6       |        |          |          |         |
|transduction                         |        |        |          |          |         |
|        Regulation of signalling     |        |        |          |5         |         |
|transduction                         |        |        |          |          |         |
|Cell cycle                           |8       |        |          |          |         |
|Cell death                           |3       |        |          |20        |4        |
|        Apoptosis                    |3       |        |          |19        |4        |
|        Negative regulation of       |        |        |          |7         |         |
|apoptosis                            |        |        |          |          |         |
|        Positive regulation of       |        |        |          |6         |         |
|apoptosis                            |        |        |          |          |         |
|Development                          |11      |4       |          |          |         |
|        Morphogenesis                |6       |        |          |31        |         |
|        Cell morphogenesis           |4       |        |          |17        |         |
|        Cell growth                  |3       |        |          |8         |         |
|        Cell migration               |        |        |          |7         |         |
|        Cell motility                |        |        |          |11        |         |
|Electron transport                   |3       |        |          |9         |         |
|Extracellular matrix organization and|        |        |          |5         |         |
|biogenesis                           |        |        |          |          |         |
|        Synapse organization and     |        |        |          |3         |         |
|biogenesis                           |        |        |          |          |         |
|Localization                         |22      |4       |          |99        |         |
|        Transport                    |21      |4       |          |86        |         |
|        Cell organization and        |14      |        |          |48        |11       |
|biogenesis                           |        |        |          |          |         |
|        Cellular Localization        |8       |        |          |19        |         |
|        Lipid transport              |        |        |          |7         |         |
|        Protein transport            |7       |        |          |21        |         |
|Metabolism                           |45      |11      |4         |211       |72       |
|        Regulation of metabolism     |16      |7       |          |57        |31       |
|        Macromolecule metabolism     |22      |6       |          |113       |45       |
|        Protein metabolism           |18      |4       |          |85        |28       |
|        Lipid metabolism             |8       |        |          |28        |4        |
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|        Steroid metabolism           |3       |        |          |11        |         |
|        Carbohydrate metabolism      |        |        |          |20        |         |
|        DNA metabolism               |        |        |          |          |11       |
|Regulation of Enzyme activity        |4       |        |          |10        |         |
|        Regulation of kinase activity|4       |        |          |6         |         |
|        Regulation of transferase    |4       |        |          |6         |         |
|activity                             |        |        |          |          |         |
|Secretion                            |        |        |          |12        |         |
|        Regulation of secretion      |        |        |          |4         |         |
|Transcription                        |16      |6       |          |48        |30       |
|Wnt receptor signalling pathway      |        |        |          |6         |         |
|        Cell-cell signalling         |        |        |          |23        |         |
|        Synaptic transmission        |        |        |          |12        |         |
Table 2: Functional Annotation Clustering of GO identifiers for regulated genes
SH-SY5Y cells were exposed to 1mM LiCl, 1mM VPA or medium for 6 or 72 hours as indicated.
RNA was extracted and gene expression monitored using Affymetrix human U133A/B
microarrays. Statistical Analysis of Microarrays (SAM) followed by interrogation of the database
for annotation, visualization and integrated discovery (DAVID) was used to identify gene
ontogeny terms that were over-represented following compound treatment.
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